Annual Meeting 8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2013
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-19311
33-0112644
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

133 Boston Post Road, Weston, Massachusetts 02493
(Address of principal executive offices; Zip Code)
    
Registrant’s telephone number, including area code: (781) 464-2000
Not Applicable
(Former name or former address, if changed since last report.)
    
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.07     Submission of Matters to a Vote of Security Holders
On June 12, 2013, Biogen Idec Inc. (the “Company”) held its Annual Meeting of Stockholders. The final voting results for this meeting are as follows:
1.
Stockholders elected twelve nominees to the Board of Directors to serve for a one-year term extending until the 2014 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:
Nominee
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
Alexander J. Denner
 
200,671,488

 
577,986

  
218,852

  
14,344,114

Caroline D. Dorsa
 
201,034,820

 
219,129

  
214,377

  
14,344,114

Nancy L. Leaming
 
201,021,123

 
228,459

  
218,744

  
14,344,114

Richard C. Mulligan
 
200,014,037

 
1,235,729

  
218,560

  
14,344,114

Robert W. Pangia
 
199,358,134

 
1,892,398

  
217,794

  
14,344,114

Stelios Papadopoulos
 
199,727,079

 
1,515,686

  
225,561

  
14,344,114

Brian S. Posner
 
199,740,106

 
1,502,446

  
225,774

  
14,344,114

Eric K. Rowinsky
 
199,926,343

 
1,322,631

  
219,352

  
14,344,114

George A. Scangos
 
200,988,795

 
257,446

  
222,085

  
14,344,114

Lynn Schenk
 
199,312,537

 
1,937,372

  
218,417

  
14,344,114

Stephen A. Sherwin
 
179,235,245

 
22,011,561

  
221,520

  
14,344,114

William D. Young
 
199,620,623

 
1,584,136

  
263,567

  
14,344,114

2.
Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2013, with the votes cast as follows: 212,343,173 votes for; 3,233,008 votes against; 236,259 abstentions; 0 broker non-votes.
3.
Stockholders approved the advisory vote on executive compensation, with the votes cast as follows: 197,974,068 votes for; 3,027,018 votes against; 466,862 abstentions; 14,344,492 broker non-votes.
4.
Stockholders reapproved the material terms of the performance goals under the Biogen Idec Inc. 2008 Performance-Based Management Incentive Plan for purposes of Section 162(m) of the Internal Revenue Code, with the votes cast as follows:197,033,424 votes for; 4,120,424 votes against; 314,100 abstentions; 14,344,492 broker non-votes.
5.
Stockholders reapproved the material terms of the performance goals under the Biogen Idec Inc. 2008 Omnibus Equity Plan for purposes of Section 162(m) of the Internal Revenue Code, with the votes cast as follows: 196,445,916 votes for; 4,704,986 votes against; 317,046 abstentions; 14,344,492 broker non-votes.
6.
Stockholders did not approve the stockholder proposal regarding adoption of a share retention policy, with the votes cast as follows: 41,204,998 votes for; 159,692,409 votes against; 570,541 abstentions; 14,344,492 broker non-votes.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOGEN IDEC INC.


By: /s/ Robert A. Licht
Robert A. Licht
Senior Vice President


Date: June 14, 2013